Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targretin Gel in Alopecia Areata
NCT00063076Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2003
- Primary completion
- Oct 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bexarotene in alopecia areata (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Tolerability of Targretin Gel 1% at 28 weeks and Efficacy of Targretin Gel 1% (Hair Regrowth) at 28 weeks. Started May 2003; status: completed.
02
Drugs
bexarotene
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT00063076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063076.